@Regeneron

Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here: https://xitter.cf/t.co/EuFDUdQQ5E

 Tarrytown, NY
regeneron.com
Joined March 2009
  • Tweets5.2K
  • Following254
  • Followers33.8K
1.9KMedia
Regeneron remains committed to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks. Read more about our latest efforts against Ebola here: bit.ly/3W3Ru8Z
Expanding our Ebola response: from the lab to the front line

ALT Expanding our Ebola response: from the lab to the front line

5
704
Late breaking at #ESMO26: We are presenting longer term results from our Phase 3 trial evaluating adjuvant immunotherapy for those with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Learn more: bit.ly/47zJ9wi
2
6
986
We are pleased to share that the European Medicines Agency’s CHMP has recommended approval of an alternative dosing regimen for our immunotherapy across its currently approved skin, lung, and cervical cancer indications. Learn more: bit.ly/4eDjCpJ
2
2
5
1,377
Today we announced positive 84-week results from a Phase 3 clinical trial investigating our therapy in adults with fibrodysplasia ossificans progressiva (FOP). Learn more about our findings at #ASBMR2026: bit.ly/4yN8RJN
1
2
1
15
1,345
At #ESMO26, we'll share new oncology research across several cancers, including late-breaking data. Together, these studies highlight the breadth of our oncology research, which spans cancer treatment to challenges beyond cancer itself. Learn more: bit.ly/4i5aIDB
13
1,293
Positive preliminary results for our investigational bispecific antibody in low-grade serous #OvarianCancer (#LGSOC) reinforce our vision to advance care for people with difficult-to-treat cancers. Learn more about the late-breaking results: bit.ly/4AKnNcT #IGCS2026
2
14
1,343
💪 At #EASD2026, we’re presenting new data from our obesity program showing the impact our investigational asset has on lean mass during GLP-1-induced weight loss in people living with obesity. Learn more: bit.ly/COURAGE-EASD
1
2
7
1,272
Today, we announced the addition of multiple next-generation, long-acting antibodies to Regeneron and @Sanofi's long-standing immunology collaboration. Read more: bit.ly/3VZMpOK
2
15
1,243
#BreakingNews: The U.S. FDA approved our medicine to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) – an ultra-rare genetic disorder. Read more: bit.ly/4xVJVyR
7
5
3
30
5,910
Join us in celebrating the 2026 Regeneron Prize for Creative Innovation winners — early-career scientists honored for their bold 'dream project; proposals in biomedical research. Meet this year’s winners. 👉 bit.ly/4vXCbuM
2026 Regeneron Prize Winners

ALT 2026 Regeneron Prize Winners

Siyuan Du, Ph.D. Stanford | Graduate Winner Dream Project: using cryo-ET technology to map the structure and function of heterchromatin

ALT Siyuan Du, Ph.D. Stanford | Graduate Winner Dream Project: using cryo-ET technology to map the structure and function of heterchromatin

Frank Peters RPI | Graduate Winner Dream Project: using 3D-printing of vascular organoids to study intact vascular networks

ALT Frank Peters RPI | Graduate Winner Dream Project: using 3D-printing of vascular organoids to study intact vascular networks

1
5
1,354
Today, we announced second quarter 2026 financial and operating results, reflecting a strong quarter of pipeline progress, commercial momentum and continued impact for people around the world. Read more: bit.ly/4h0JApi
2026 second quarter financial and operating results

ALT 2026 second quarter financial and operating results

$4.3B revenues in Q2 2026 increasing 17% versus Q2 '25

ALT $4.3B revenues in Q2 2026 increasing 17% versus Q2 '25

"Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases." Leonard Schleifer, MD, PhD Board co-Chair, President and Chief Executive Officer

ALT "Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases." Leonard Schleifer, MD, PhD Board co-Chair, President and Chief Executive Officer

"Given Regeneron's strong financial position, we continue to invest confidently in our pipeline, U.S. manufacturing, and external innovation, while returning capital to shareholders." Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer

ALT "Given Regeneron's strong financial position, we continue to invest confidently in our pipeline, U.S. manufacturing, and external innovation, while returning capital to shareholders." Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer

1
7
1,520
We're pleased to announce that regulatory submissions have been accepted for review by the U.S. FDA and EMA for our novel siRNA investigational medicine for adult patients with generalized myasthenia gravis (#gMG). Read more: bit.ly/43Q994B
2
1
23
6,845
Great music and great science demand practice and precision, and we follow the science by letting data set the tempo. This June, our teams share new work in two major music cities. Learn more about our latest advancements: bit.ly/3QoXjv7
1
4
1,288
A Regeneron antibody was recommended by the @WHO for investigational use in response to the current Bundibugyo Ebola outbreak. Read more: bit.ly/4aafYRV
A Regeneron antibody has been recommended by the World Health Organization for investigational use in response to the current Bundibugyo Ebola outbreak in DRC and Uganda.

ALT A Regeneron antibody has been recommended by the World Health Organization for investigational use in response to the current Bundibugyo Ebola outbreak in DRC and Uganda.

5
1
12
1,416
The European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application of our investigational gene therapy to treat biallelic OTOF variant-associated #hearingloss.
 
Read more: bit.ly/4a4WdLA
6
1,139
Today we announced positive results from the LINKER-AL2 clinical trial investigating our bispecific therapy in second-line-plus systemic amyloid light chain #amyloidosis. Learn more ahead of the oral presentation at #ASCO26: bit.ly/4nKNB2n
1
12
1,141
Today we announced a collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform. Learn more: bit.ly/4wyoeEW
Regeneron announces collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform.

ALT Regeneron announces collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform.

Regeneron announces collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform.

ALT Regeneron announces collaboration with Parabilis Medicines that combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform.

1
1
5
1,079
Today, we’re presenting late-breaking data at Digestive Disease Week from an innovative Phase 4 study in adults with eosinophilic esophagitis, a progressive disease causing narrowing of the esophagus. Read more: bit.ly/4d13BIz CC: @sanofi #DDW2026
New Phase 4 data in eosinophilic esophagitis shared at Digestive Disease Week 2026

ALT New Phase 4 data in eosinophilic esophagitis shared at Digestive Disease Week 2026

1
8
1,129
Today, we announced our first quarter 2026 financial and operating results, detailing breakthrough innovation, strong commercial performance and continued momentum across our pipeline and portfolio. Read more: bit.ly/4ecsovE
2026 First Quarter Financial and Operating Results

ALT 2026 First Quarter Financial and Operating Results

$3.6B revenues in Q1 2026 increasing 19% versus Q1 '25

ALT $3.6B revenues in Q1 2026 increasing 19% versus Q1 '25

"In the first quarter of this year, we were able to achieve strong double-digital growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development." Leonard Schleifer, MD, PhD Board co-Chair, President and Chief Executive Officer

ALT "In the first quarter of this year, we were able to achieve strong double-digital growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development." Leonard Schleifer, MD, PhD Board co-Chair, President and Chief Executive Officer

"Regeneron delivered strong first quarter 2026 financial results. In addition to driving commercial execution, we remain focused on investing in our internal engine, returning capital to shareholders, expanding our R&D and manufacturing footprint, and preserving financial flexibility." Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer

ALT "Regeneron delivered strong first quarter 2026 financial results. In addition to driving commercial execution, we remain focused on investing in our internal engine, returning capital to shareholders, expanding our R&D and manufacturing footprint, and preserving financial flexibility." Christopher Fenimore Executive Vice President, Finance and Chief Financial Officer

6
959
Today the U.S. FDA approved our medicine – the first and only gene therapy for genetic #hearingloss – signaling a new era where enabling 24/7 natural hearing is now possible. We are proud to make this available for free in the U.S. Read more: bit.ly/4e6f2Rx
27
118
40
426
250,441
Load more